Pharmacogenomics: From Bench to Bedside (Part 2)
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN:0853-9999-17-047-L01-P) 1.5
Sunday, October 8
8:00 AM - 9:45 AM
Pharmacogenomics (PGx), the study of how one’s genes may affect an individual’s response to medication, has reached the translational stage for various specialties in medicine. Over thirty years of research has led to promising advances in the clinical practice. This conference provides the background, resources and practical application examples to implement pharmacogenomics and make a difference in patient lives. Mayo Clinic experts, with experience leading the implementation of PGx, will provide practical guidance on a range of topics, background and research including: when to order testing, drug/gene selection, informatics, and case study working sessions.
Sunday, October 8th, 2017
8:00 am Welcome and Review
Pharmacogenomics: From Bench to Bedside Part II
• Outline example institutional resources and clinical tools to assist in developing and/or implementing pharmacogenomic services.
• Identify examples of the use of genome data-rich model systems and genome-wide techniques to gain insight into mechanisms responsible for variation in response to drug therapy.
• Describe the major barriers to the routine implementation of pharmacogenomics across practice sites
8:15 am 1.Systems & Tools for Implementation
Wayne (Nick) T. Nicholson, M.D., Pharm.D., R.Ph.
8:55 am Q&A
9:05 am 2.Research in Pharmacogenomics
Leiwei Wang, M.D., Ph.D.
9:35 am Q&A
9:45 am Break
Clinical Case Applications in Pharmacogenomics Part II
• Define the role of pharmacogenomics testing in cardiovascular drug response.
• Utilize genetics to minimize adverse events and maximize drug efficacy.
• Understand the limitation of pharmacogenomics testing in practice of cardiovascular disease
• Provide examples of how pharmacogenomic testing can be utilized prescribing medications for patients with HIV
10:00 am 3.Cardiology
Fadi E. Shamoun, M.D.
11:00 am 4.HIV
John D. Zeuli, Pharm.D., R.Ph.
12:00 Noon Luncheon
Clinical Case Applications in Pharmacogenomics Part III
• Outline evidence‐based guidelines and literature to formulate patient‐specific medication regimen plans based on pharmacogenomic test results and other patient‐specific factors
• Identify variants and their impact on medications for the treatment of pain.
1:00 pm 5.Cancer/TPMT
Richard Weinshilboum, M.D.
2:00 pm 6.Pain
Wayne (Nick) T. Nicholson, M.D., Ph.D.
3:00 pm Break
Clinical Case Applications in Pharmacogenomics Part IV
• Describe current applications of pharmacogenomics in psychiatry practice
• Identify pharmaco-genes of clinical utility associated with pharmacogenomics testing for psychiatric medications
• Discuss impact on medication optimization through patient cases
3:15 pm 7. Transplant
Christopher B. Grilli, Pharm.D., R.Ph.
4:15 pm 8. Psych
Adrijana Kekic, Pharm.D.
5:15 pm Closing Comments and Adjourn
- Outline example institutional resources and clinical tools to assist in developing and/or implementing pharmacogenomic services.
- Identify examples of the use of genome data-rich model systems and genome-wide techniques to gain insight into mechanisms responsible for variation in response to drug therapy.
- Describe the major barriers to the routine implementation of pharmacogenomics across practice sites